5.1 Carcinogenesis: How Breast Cancer Develops and Spreads
Key Takeaways
Carcinogenesis is a multistep process of initiation, promotion, and progression in which accumulated genetic and epigenetic changes give cells the hallmarks of cancer.
Oncogenes such as ERBB2 (HER2) and PIK3CA drive growth when activated, while tumor suppressor genes such as TP53, BRCA1, BRCA2, PTEN, and CDH1 promote cancer when both copies are lost.
About 5% to 10% of breast cancers arise from inherited germline variants; most mutations in a tumor are somatic and are not passed to children.
Loss of E-cadherin and epithelial-to-mesenchymal transition help cancer cells invade, and breast cancer spreads most often to bone, lung, liver, and brain.
Why Carcinogenesis Is on a Nursing Exam
Patients ask, "Why did I get this?" and "Will my children inherit it?" Understanding carcinogenesis lets the nurse explain why tumor genomic testing differs from germline genetic testing, why estrogen matters, why some cancers spread to bone and others to the brain, and how targeted drugs match specific molecular defects.
The Multistep Model
Cancer develops over years through accumulated damage:
- Initiation: a carcinogen, replication error, or inherited variant causes a permanent DNA change in a cell.
- Promotion: factors such as estrogen, obesity-related inflammation, or alcohol stimulate proliferation of the initiated cell, expanding a clone.
- Progression: additional mutations and epigenetic changes produce invasion, genomic instability, and metastatic ability.
By the time a breast tumor is about 1 cm, it contains roughly one billion cells after about 30 doublings, which is why a "new" cancer has usually been growing for years.
The Hallmarks of Cancer
Hanahan and Weinberg described capabilities that malignant cells acquire:
| Hallmark | Breast cancer example | Targeted approach |
|---|---|---|
| Sustained proliferative signaling | ER signaling; HER2 amplification | Endocrine therapy; trastuzumab |
| Evading growth suppressors | Cyclin D1–CDK4/6 inactivating Rb | CDK4/6 inhibitors |
| Resisting cell death | PI3K/AKT survival signaling | Alpelisib, capivasertib, inavolisib |
| Replicative immortality | Telomerase activation | Investigational |
| Inducing angiogenesis | VEGF release | Studied in breast cancer; not standard |
| Invasion and metastasis | Loss of E-cadherin | Understanding lobular spread |
| Evading immune destruction | PD-L1 expression | Pembrolizumab in TNBC |
| Genome instability (enabling) | BRCA-related repair defects | PARP inhibitors, platinum |
| Tumor-promoting inflammation (enabling) | Obesity-associated inflammation | Weight management and activity |
Oncogenes and Tumor Suppressor Genes
- Proto-oncogenes normally promote controlled growth. When amplified or mutated they become oncogenes that act like a stuck accelerator. Only one altered copy is needed. Examples: ERBB2 (HER2) amplification in 15% to 20% of breast cancers, PIK3CA activating mutations in about 40% of HR-positive, HER2-negative advanced cancers, CCND1 (cyclin D1) amplification, and MYC.
- Tumor suppressor genes normally act as brakes or repair crews. Cancer usually requires loss of both copies, the two-hit hypothesis described by Knudson. Examples: TP53 (mutated in about 80% of triple-negative cancers), BRCA1, BRCA2, PTEN, CDH1, and RB1.
- DNA repair genes such as BRCA1, BRCA2, and PALB2 maintain genome stability; their loss creates the homologous recombination deficiency that PARP inhibitors exploit.
Germline Versus Somatic Mutations
| Feature | Germline | Somatic |
|---|---|---|
| Where present | Every cell, from conception | Only tumor cells |
| Inherited or passed on | Yes, 50% chance to each child for autosomal dominant genes | No |
| How tested | Blood or saliva germline panel | Tumor tissue or circulating tumor DNA (liquid biopsy) |
| Example use | BRCA2 result guides family testing and olaparib eligibility | PIK3CA or ESR1 result guides targeted therapy |
In an inherited syndrome, the first hit is present at birth, so only one more hit is needed. That explains earlier onset, bilateral disease, and multiple primary cancers. Tumor sequencing can reveal a possible germline variant, which then needs confirmatory germline testing and genetic counseling.
Hormonal Carcinogenesis
Estrogen promotes breast cancer in two ways: it stimulates proliferation of estrogen receptor-positive cells (more divisions mean more chances for replication errors), and some estrogen metabolites are genotoxic. Progesterone also drives proliferation through RANKL signaling. This explains why early menarche, late menopause, nulliparity, combined hormone therapy, and postmenopausal obesity raise risk, and why endocrine therapy and oophorectomy lower it. Ionizing radiation, especially before age 30, and alcohol (through acetaldehyde and higher estrogen levels) are other established carcinogens.
Progression Pathways
Breast cancers evolve along two broad routes. The low-grade (luminal) pathway runs from columnar cell lesions and atypical ductal hyperplasia through low-grade DCIS to low-grade, ER-positive invasive cancer. The high-grade pathway often produces high-grade DCIS and invasive cancers with TP53 mutation, HER2 amplification, or a triple-negative phenotype; some triple-negative cancers arise without a recognizable precursor.
Invasion and the Metastatic Cascade
- Local invasion: tumor cells break through the basement membrane. Epithelial-to-mesenchymal transition (EMT) and loss of E-cadherin loosen cell-to-cell adhesion.
- Intravasation into lymphatics and blood vessels (seen on pathology as lymphovascular invasion).
- Survival in the circulation as circulating tumor cells.
- Extravasation at a distant site.
- Colonization: some cells remain dormant for years, which explains late recurrences of ER-positive cancer.
Paget's 1889 "seed and soil" idea still holds: tumor cells grow where the organ environment supports them. Luminal cancers favor bone; HER2-positive and triple-negative cancers more often involve liver, lung, and brain; lobular cancers can spread to the peritoneum, gastrointestinal tract, and ovaries.
Nursing Applications
- Explain that most breast cancers are not inherited, but that a family history or tumor finding can prompt germline testing.
- Clarify that tumor (somatic) testing, such as ESR1 testing by liquid biopsy at progression, guides treatment and does not show inherited risk.
- Connect biology to therapy when teaching: "Your tumor has too many HER2 receptors, and this medicine blocks them."
Beyond Mutations: Epigenetics, Heterogeneity, and the Microenvironment
Epigenetic changes alter gene expression without changing the DNA sequence. Examples include DNA methylation that silences tumor suppressor genes (such as BRCA1 promoter methylation in some sporadic triple-negative cancers) and histone modifications that open or close chromatin. Epigenetic silencing can mimic a mutation, which is one reason some sporadic tumors show "BRCAness" and respond to platinum or PARP-directed strategies.
Tumor heterogeneity means a single cancer contains subclones with different mutations. Treatment selects for resistant subclones: ESR1 mutations emerge during aromatase inhibitor therapy, and HER2 expression can vary across a tumor or change at recurrence. This is why metastatic disease is biopsied to recheck ER, PR, and HER2, and why circulating tumor DNA is tested again at progression.
The tumor microenvironment includes cancer-associated fibroblasts, immune cells, blood vessels, and extracellular matrix. Fibroblasts create the desmoplastic reaction that makes ductal cancers feel hard and cause skin dimpling. Immune cells can attack the tumor (tumor-infiltrating lymphocytes predict better response in triple-negative disease) or be suppressed through checkpoints such as PD-1 and PD-L1. Hypoxia inside growing tumors drives angiogenesis and aggressive behavior.
Dormancy explains why some ER-positive cancers recur 10 or 20 years after diagnosis: disseminated tumor cells can lie quiet in bone marrow for years before the microenvironment allows them to grow. Extended endocrine therapy and adjuvant bisphosphonates target this biology.
Next-generation sequencing of a patient's metastatic tumor shows a PIK3CA mutation. The patient asks whether her daughters should be tested for it. What is the most accurate response?
Yes, because every mutation found in a tumor is inherited and present in all family members.
This is a somatic tumor mutation that guides treatment; it is not inherited, although germline testing may still be offered based on her personal and family history.
No testing is ever useful for relatives of breast cancer patients.
Her daughters should start PI3K inhibitor therapy to prevent cancer.
Which molecular change best explains why invasive lobular carcinoma cells infiltrate tissue in single-file lines?
Amplification of the ERBB2 oncogene
Activating mutation of PIK3CA
Loss of E-cadherin, which reduces cell-to-cell adhesion
Overexpression of vascular endothelial growth factor
According to the two-hit hypothesis, why do BRCA1 carriers often develop breast cancer at younger ages than people with sporadic cancer?
They inherit one nonfunctional copy in every cell, so only one additional hit is needed to lose tumor suppressor function.
BRCA1 is an oncogene that needs only one activating mutation.
Their tumors grow faster only because they produce more estrogen.
They lack both copies of BRCA1 from birth in every cell.
Sections you finish are checked off in the contents.